tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Marc Frahm, 4 are a BUY (40%), 6 are a HOLD (60%).
Analyst Marc Frahm, currently employed at TD COWEN, carries an average stock price target met ratio of 66.67% that have a potential upside of 22.93% achieved within 111 days. Previously, Marc Frahm worked at COWEN.
Marc Frahm’s has documented 20 price targets and ratings displayed on 5 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on TBPH, Theravance Biopharma at 06-Aug-2024.
Analyst best performing recommendations are on TBPH (THERAVANCE BIOPHARMA).
The best stock recommendation documented was for TBPH (THERAVANCE BIOPHARMA) at 9/15/2021. The price target of $8 was fulfilled within 23 days with a profit of $1.23 (18.17%) receiving and performance score of 7.9.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$15
$5.48 (57.56%)
$15
2 months 5 days ago
(16-Sep-2024)
3/14 (21.43%)
$6.88 (84.73%)
35
Hold
$9
$-0.52 (-5.46%)
$10
3 months 15 days ago
(06-Aug-2024)
4/6 (66.67%)
$1.17 (14.94%)
96
Buy
$10
$0.48 (5.04%)
$14
3 months 15 days ago
(06-Aug-2024)
0/3 (0%)
$2.17 (27.71%)
Sell
$10
$0.48 (5.04%)
$10
2 years 3 months 27 days ago
(25-Jul-2022)
2/8 (25%)
$0.76 (8.23%)
70
Buy
$12
$2.48 (26.05%)
$10
2 years 5 months 29 days ago
(23-May-2022)
3/8 (37.5%)
$2.6 (27.66%)
85
Which stock is Marc Frahm is most bullish on?
What Year was the first public recommendation made by Marc Frahm?
